Navigation Links
Penn Dental Medicine, CHOP Team Show HIV/AIDS Drugs Interfere with Brain's 'Insulation'
Date:1/18/2016

PHILADELPHIA, Jan. 18 2016 /PRNewswire/ -- Antiretroviral therapies (ART) have enabled people with HIV/AIDS to live much longer lives, essentially transforming the disease into a chronic condition. Yet concerns for these patients remain. Up to half of people with HIV on these drug regimens have some sort of cognitive impairment, such as memory loss or problems with executive functioning, despite the virus being almost undetectable in their bodies.

In a new study, researchers from Penn Dental Medicine and The Children's Hospital of Philadelphia teamed up to investigate the underlying reasons for these impairments. They found that commonly used antiretroviral medications (protease inhibitors Ritonavir and Lopinavir) disrupted the differentiation of oligodendrocytes, crucial brain cells that manufacture myelin, the fatty material that serves to insulate neurons, helping them transmit signals in the brain fast and efficiently.

This disruption, the researchers said, may be responsible for some of the cognitive problems that HIV patients experience, and point to a need for rethinking how HIV drugs are designed and prescribed, particularly for children on ART, in whom myelin is still forming at high rates.

"Pharmaceutical companies have done an amazing job developing drugs to make HIV patients live longer, but we're not done," said Kelly L. Jordan-Sciutto, professor and chair of Penn Dental Medicine's Department of Pathology, who co-led the research with Judith B. Grinspan, a research scientist at CHOP and professor of neurology at Penn's Perelman School of Medicine. "The message we want to get out there is that we want to make these patients' lives better while they are on ART."

The research was published this November in the Journal of Neuropathology and Experimental Neurology.

The researchers have yet to determine a mechanism by which myelin protein levels are altered with ART, but are investigating a number of avenues. They are also evaluating how different HIV medications can affect oligodendrocyte and myelin formation, as the recommended drug cocktails frequently change.

The implications of these findings may be particularly important for pediatric patients, some of whom may have been on ART from birth. Since HIV-infected children exhibit higher rates of neurocognitive disorders such as seizures, depression, and ADHD, the researchers stress that a revised look at treatments for pediatric patients may be warranted, or an additional therapy to prevent the white matter loss in both adults and children could be developed to go hand in hand with the ART.

Contact:
Beth Adams
215-573-8224
adamsnb@upenn.edu


'/>"/>
SOURCE Penn Dental Medicine
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. Abaxis, Inc. to Present at the Stifel Annual Dental & Veterinary Conference
2. Heska Corporation to Present at the Stifel Dental & Veterinary Conference
3. Stanley Bergman Delivers Commencement Address At Stony Brook School Of Dental Medicine
4. Umbie DentalCare - Multiple Opportunities One Solutions
5. GRW bearing lubrication tests yield maximum wear life for medical and dental instruments
6. SmileBest Dental & Orthodontics Opens Their First Office in Hurst, Texas
7. Henry Schein Dental And American Dental Hygienists Association Host "Dream Center" To Mark 100th Anniversary Of Profession
8. TopProdeals.com Rises to Top as Discount Dental Supply Leader
9. Global Dental Restorative Supplies Industry
10. Global Dental Orthodontic Supplies Industry
11. Henry Schein Chairman Of The Board & CEO Receives Centennial Recognition Award For Extraordinary Commitment To The National Dental Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2017)... Fix Inc. (" Fortuna "), a private, clinical-stage biotech ... need for embryonic and fetal stem cells by using direct ... Fortuna announced today the launch of its Scientific ... PhD; Father Kevin FitzGerald , S.J., PhD; Col. (R) ... Giordano , PhD. "We are excited and honored ...
(Date:5/4/2017)... , May 4, 2017  DarioHealth Corp. (NASDAQ: ... health and big data solutions, today announced that it ... Company, and STI Technologies Limited to lower diabetes healthcare ... Through STI,s innoviCares card, which is available throughout all ... DarioHealth customers will be eligible for additional savings when ...
(Date:5/3/2017)... ROCKVILLE, Md. , May 3, 2017 /PRNewswire/ ... revenue growth of nine percent next year and ... solid organ and hematopoietic stem cell (HSCT) or ... and donor. Molecular testing technologies are well-suited for this ... healthcare-only market research publisher Kalorama Information. The various ...
Breaking Medicine Technology:
(Date:5/23/2017)... ... ... Axiad IDS , a leading provider of trusted identities for enterprise, ... a “Top 25 Cybersecurity Companies 2017.” Axiad IDS received this honor in ... address potential cybersecurity threats before they happen. The annual list of top ...
(Date:5/23/2017)... (PRWEB) , ... May 23, 2017 , ... ... the pharmaceutical and medical device sectors, today announced the winners of its 3rd ... Entrepreneurs) represent the most influential people in the healthcare industry today. , Out ...
(Date:5/23/2017)... ... May 23, 2017 , ... New England Journal Of Medicine Confirms Viability of ... Response”, -The Rory Staunton Foundation Calls on Health & Human Services, Tom Price to ... ( http://www.rorystauntonfoundation.org ) today reported on a new study released on May 21, 2017 ...
(Date:5/23/2017)... ... May 23, 2017 , ... The National ... is pleased to announce the organization’s Certified Strength Coach credential has earned accreditation ... Coach (CSC) program validates the competency of qualified candidates for jobs in the ...
(Date:5/23/2017)... ... May 23, 2017 , ... ... Reconstructive Surgeon Dr. Kevin Sadati, is pleased to announce a new treatment option ... and elastin in their face, neck, and body through a virtually pain-free, non-surgical ...
Breaking Medicine News(10 mins):